This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Psoriasis  • Phototherapy  • Alert me on articles by topic

We're Halfway There, With a Long Way to Go

Joel M. Gelfand, MD, MSCE

Arch Dermatol. 2007;143(9):1191-1193.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Over the last 30 years, the landmark PUVA [psoralen–UV-A] Follow-up Study has demonstrated the importance of clinical epidemiology research in making informed treatment decisions for patients with psoriasis. When PUVA was first introduced, psoriasis was widely believed to be an epidermal cell proliferation disorder, and there were few systemic treatment options available at that time.¹ Thirty years later, psoriasis is believed to be an immunologic disorder, and more new systemic therapies have been approved to treat it in the last 4 years than in the previous 30 years combined.^2-8 Our objective criterion regarding which patients have severe psoriasis and therefore are candidates for systemic therapy has also evolved during this period, declining from 20% to 30% body surface area (BSA) in the 1970s to 1990s to 5% more recently.^9-10 With the increasing recognition of the impact of psoriasis on health-related quality of life and the . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Clinical Severity of Psoriasis in Last 20 Years of PUVA Study
Tamar Nijsten, Caspar W. N. Looman, and Robert S. Stern
Arch Dermatol. 2007;143(9):1113-1121.
ABSTRACT | FULL TEXT